167 related articles for article (PubMed ID: 11803167)
1. Vitamin D analogs for the treatment of secondary hyperparathyroidism.
Slatopolsky E; Brown AJ
Blood Purif; 2002; 20(1):109-12. PubMed ID: 11803167
[TBL] [Abstract][Full Text] [Related]
2. New vitamin D analogs.
Slatopolsky E; Finch J; Brown A
Kidney Int Suppl; 2003 Jun; (85):S83-7. PubMed ID: 12753273
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats.
Slatopolsky E; Cozzolino M; Finch JL
Kidney Int; 2002 Oct; 62(4):1277-84. PubMed ID: 12234297
[TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D analogues for the management of secondary hyperparathyroidism.
Martin KJ; González EA
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
[TBL] [Abstract][Full Text] [Related]
6. Effect of 2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism.
Slatopolsky E; Finch JL; Brown AJ; Ritter CS; Mizobuchi M; Plum LA; Clagett-Dame M; Sicinski RR; DeLuca HF
J Bone Miner Res; 2007 May; 22(5):686-94. PubMed ID: 17444814
[TBL] [Abstract][Full Text] [Related]
7. Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats.
Slatopolsky E; Finch J; Ritter C; Takahashi F
Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S40-7. PubMed ID: 9808142
[TBL] [Abstract][Full Text] [Related]
8. Strategies to minimize bone disease in renal failure.
Martin KJ; González EA
Am J Kidney Dis; 2001 Dec; 38(6):1430-6. PubMed ID: 11728986
[TBL] [Abstract][Full Text] [Related]
9. [Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient].
Brancaccio D; Cozzolino M; Galassi A; Bellasi A; Carpani P; Gallieni M
G Ital Nefrol; 2003; 20 Suppl 22():S12-6. PubMed ID: 12851915
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients.
Coyne DW; Grieff M; Ahya SN; Giles K; Norwood K; Slatopolsky E
Am J Kidney Dis; 2002 Dec; 40(6):1283-8. PubMed ID: 12460048
[TBL] [Abstract][Full Text] [Related]
11. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
Goldenberg MM
Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413
[TBL] [Abstract][Full Text] [Related]
12. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
13. New strategies for the treatment of secondary hyperparathyroidism.
Akizawa T; Shiizaki K; Hatamura I; Kamimura M; Mizobuchi M; Narukawa N; Sumikado S; Sakaguchi T; Negi S; Ogata H; Kinugasa E
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S100-3. PubMed ID: 12612963
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D metabolites and/or analogs: which D for which patient?
Mazzaferro S; Goldsmith D; Larsson TE; Massy ZA; Cozzolino M
Curr Vasc Pharmacol; 2014 Mar; 12(2):339-49. PubMed ID: 23713876
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone.
Finch JL; Brown AJ; Slatopolsky E
J Am Soc Nephrol; 1999 May; 10(5):980-5. PubMed ID: 10232683
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D analogs: perspectives for treatment.
Brown AJ; Slatopolsky E
Miner Electrolyte Metab; 1999; 25(4-6):337-41. PubMed ID: 10681662
[TBL] [Abstract][Full Text] [Related]
17. 1,25-(OH)2-16ene-23yne-D3 reduces secondary hyperparathyroidism in uremic rats with little calcemic effect.
Lippuner K; Perrelet R; Casez JP; Popp A; Uskokovic MR; Jaeger P
Horm Res; 2004; 61(1):7-16. PubMed ID: 14646396
[TBL] [Abstract][Full Text] [Related]
18. [Vitamin D treatment and renal osteodystrophy: indications and modalities].
Fournier A; Morinière P; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B
Nephrologie; 1995; 16(2):165-90. PubMed ID: 7753302
[TBL] [Abstract][Full Text] [Related]
19. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism.
Brown AJ; Coyne DW
Treat Endocrinol; 2002; 1(5):313-27. PubMed ID: 15832485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
